13242-30-3 Usage
Description
Fluocinolone Acetonide-21-aldehyde is a corticosteroid derivative of Fluocinolone Acetonide, characterized by the presence of an aldehyde functional group at the 21st position. It exhibits potent anti-inflammatory and immunosuppressive properties, making it a valuable compound in the field of dermatology.
Uses
Used in Dermatology:
Fluocinolone Acetonide-21-aldehyde is used as a topical corticosteroid for the treatment of various skin conditions, including eczema, psoriasis, and contact dermatitis. It works by reducing skin inflammation, relieving itching, and suppressing the immune response, thereby promoting healing and improving the overall skin condition.
Used in Pharmaceutical Industry:
Fluocinolone Acetonide-21-aldehyde is utilized in the development of pharmaceutical formulations, such as creams, ointments, and gels, to target specific skin areas and provide localized relief from inflammation and itching. Its aldehyde group may also offer potential for chemical modifications, allowing for the creation of new drug derivatives with improved properties or alternative therapeutic applications.
Used in Research and Development:
Fluocinolone Acetonide-21-aldehyde serves as a valuable research tool for studying the mechanisms of corticosteroid action, as well as for the development of new anti-inflammatory and immunosuppressive agents. Its unique structure allows scientists to investigate the role of the aldehyde group in modulating the compound's biological activity and to explore its potential for use in other therapeutic areas.
Check Digit Verification of cas no
The CAS Registry Mumber 13242-30-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,2,4 and 2 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 13242-30:
(7*1)+(6*3)+(5*2)+(4*4)+(3*2)+(2*3)+(1*0)=63
63 % 10 = 3
So 13242-30-3 is a valid CAS Registry Number.
13242-30-3Relevant articles and documents
DRUG DERIVATIVES
-
Paragraph 0501; 0502, (2013/09/12)
The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.
A concise access to a new class of selective anti-inflammatory steroid derivatives
Quiclet-Sire, Beatrice,Zard, Samir Z.
, p. 1173 - 1174 (2007/10/03)
The 17β-thiomethyl-16α,17α-ketal motif of a new class of selective anti-inflammatory androstane derivatives useful in the treatment of asthma is readily constructed by a new radical degradation of the corticosteroid side chain.
